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Summary: We report the case of a 34-year-old man with extreme hypertriglyceridaemia (276.6 mmol/1) that was
corrected by diet and triple-drug therapy. No primary defect could be found despite an intensive biochemical and
genetic evaluation. Early in the time course of triglyceride-lowering therapy, the composition and concentration of
different lipoprotein species changed markedly. His lipoprotein profile mimicked type III hyperlipidaemia, then
familial hypercholesterolaemia, and finally hyperalphalipoproteinaemia. The increase in LDL cholesterol and apoli-
poprotein B was paralleled by a sixfold increase in lipoprotein(a). We conclude that these different forms of hyp-
ercholesterolaemia disappear solely with a continuation of the triglyceride-lowering therapy.
Introduction
Patients with marked hypertriglyceridaemia are at
increased risk for developing acute pancreatitis (1). The
cause of the pancreatitis has been attributed to hydroly-
sis of chylomicron-triglycerides in the pancreas by intra-
vascular pancreatic lipase. The consequent release of
free fatty acids may cause microthrombosis leading to
pancreatic necrosis. Because of this, patients with tria-
cylglycerol concentrations exceeding 11.3 mmol/1 must
be treated both with a lipid-free diet and with triglycer-
ide-lowering drugs (2). As a side effect of triglyceride-
lowering therapy, high-density lipoprotein (HDL) cho-
lesterol is regularly increased; and low-density lipopro-
tein (LDL) cholesterol may also be increased, although
rarely to above-normal levels.
Case Report
Presentation and history
The patient was a non-obese 34-year-old man, who had triacylglyc-
erol and cholesterol values of 276.6 mmol/1 and 70.3 mmol/1,
respectively, at admission. He had lost 3 kg of body weight during
the previous weeks and complained of lack of appetite. He drank
1 litre of beer per day. The patient had no history of polydipsia,
diarrhea, vertigo, chest of pain or fatigue, and was not taking any
medication. The physical examination showed no abnormalities ex-
cept eruptive xanthomata of the right hand. His father died at 47
years of age of sudden cardiac death. His brother had a partial
resection of the pancreas at the age of 30 after acute pancreatitis.
Lipid values for the brother and both parents are not known. The
patient's only child had normal triacylglycerol values, but her LDL
cholesterol concentration (3.70 mmol/1) was above the 95th percen-
') Enzymes
γ-Glutamyltransferase (EC 2.3.2.2)
Alanine aminotransferase (EC 2.6.1.2)
Amylase (EC 3.2.1)
Aspartate aminotransferase (EC 2.6.1.1)
Cholesterol esterase (EC 3.1.1.13)
Lipase (EC 3.1.1.3)
Lipoprotein lipase (EC 3.1.1.34)
tile for a 9-year-old girl (3). None of his female relatives had preg-
nancy-associated pancreatitis (4).
Laboratory analysis
Serum and plasma were isolated by low spin centrifugation, and
the samples were stored at 4 °C. Analysis of lipoproteins was
performed within 24 h after blood drawing as described pre-
viously (i. e., HDL were analyzed by removal of very-low-den-
sity lipoproteins (VLDL) and chylomicrons by ultracentrifugation
followed by precipitation of apolipoprotein B-containing lipopro-
teins of the fraction d> 1.006 kg/1 (5). Apolipoproteins were
determined by nephelometry (BNA 100, Behring). To eliminate
the interference of light scattering by triglyceride-rich lipopro-
teins, a clearing buffer containing detergent and cholesterol ester-
ase1) was added to the sample before nephelometry (6). Lipopro-
tein(a) (Lp(a)) was measured by a radioimmunoassay (Phar-
macia). No interference by chylomicrons could be demonstrated
for this assay by adding chylomicrons to samples with known
Lp(a) concentrations, similar to the procedures described in 1. c.
(7). Apolipoprotein(a) phenotyping was performed by western
blot analysis (5) and revealed heterozygosity for the isoforms
S2/S2.5. The following serum assays were performed after re-
moval of the chylomicron fraction (Sf > 400) by ultracentrifuga-
tion and revealed results within the reference range: creatinine,
urea, thyrotropin, free thyroxine, triiodothyronine, C-reactive pro-
tein, insulin concentrations, amylase1), lipase1), aspartate amino-
transferase1), and alanine aminotransferase1). Erythrocyte sedi-
mentation rate, hepatitis serology, oral glucose test loads, and
urinalysis were within the reference range.
Hyperglycerolaemia, which can falsely be taken for hypertriglyc-
eridaemia, was excluded by normal glycerol values (8). Glycerol
was measured under conditions corresponding to the enzymatic
triacylglycerol assay (Boehringer Mannheim) omitting lipase. The
γ-glutamyltransferase1), which was elevated (681 U/l) at the first
presentation (reference value ^ 27 U/l), was within the reference
range after 6 weeks. On three occasions, plasma lipolytic activity
(20 min after the i. v. injection of 100 IU of heparin per kg
body weight) was normal in vivo (more than fourfold increase
in free glycerol and free fatty acids) and in vitro (measured by
the release of free fatty acids from glycerol tri[l-14C]oleate
emulsion (9)). Sequencing of all 10 exons of the lipoprotein
lipase1) gene from white blood cell genomic DNA showed no
mutation (9), and the demonstration of two polymorphisms ex-
cluded the absence of one copy of the lipoprotein lipase gene.
He was homozygous for the apolipoprotein E isoform E3 (10),
and isoelectric focusing and immunofixation of VLDL also ex-
cluded apolipoprotein C-II deficiency.
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Treatment
The patient was advised to keep an almost lipid-free diet (11). In
addition to dietary therapy, the patient was treated with the combi-
nation of gemfibrozil (900 mg/day) (12), acipimox (750 mg/day)
(13), and marine oils (14) (co-3 fatty acids: eicosapentaenoic acid
(1050 mg/day) and docosahexaenoic acid (750 mg/day)).
Outcome
Triacylglycerol values decreased to levels in the reference range
within 3 weeks (fig. la). Concomitantly free fatty acids also de-
creased. After normalization of triacylglycerol values, acipimox
and subsequently marine oils were discontinued (fig. la). The cho-
lesterol decrease in the different lipoprotein fractions, however,
was noticeably different (fig. Ib). After 15 days of treatment, LDL
cholesterol rose to a maximum of 18.25 mmol/1, and the LDL par-
ticles became markedly cholesterol-enriched. The ratio of choles-
terol to triacylglycerols was more than twice the reference value
(fig. Ic). The increases in LDL cholesterol and LDL apolipoprotein
B were accompanied by a sixfold rise in Lp(a) (fig. Id).
At the start of therapy, HDL were small and cholesterol-poor (0.26
mmol/1), whereas the apolipoprotein A-I concentration (1.23 g/1)
was close to the lower reference limit (reference range 1.25 — 1.60
g/1). With therapy, however, HDL became cholesterol-rich and tri-
glyceride-poor (fig. Ic). Apolipoprotein A-I concentrations
increased to high values (2.52 g/1 on day 82), but because of a
greater increase in cholesterol, the ratio of apolipoprotein A-I to
HDL cholesterol was below normal. The ratio of free cholesterol
to total cholesterol did not change during therapy.
Eight months after the start of therapy, a trial period without any
drug therapy led again to a marked triglyceridaemia (26.69
mmol/1). When triple-drug therapy was restarted, the pattern of li-
poprotein decrease and increase was similar to that of the first
episode, but triacylglycerol and LDL cholesterol concentrations
normalized within a shorter period of time. LDL cholesterol
increased from 0.41 mmol/1 to 9.05 mmol/1 within 2 weeks and
returned to 3.28 mmol/1 4 weeks after restart of therapy. During
the next 6 months, while on combination therapy with gemfibrozil
and marine oils, his lipid values remained normal except for ele-
vated HDL (HDL-cholesterol 2.07-2.87 mmol/1) and elevated free
fatty acids (1.73-3.33 mmol/1) (reference range 0.19-1.20
mmol/1).
Discussion
The cause for the dyslipidaemia in our patient remains
unknown. He did not have a primary metabolic defect,
but this finding is characteristic for patients with type V
hyperlipidaemia (15). In particular, no defects in lipo-
protein lipase or its essential cofactor (apolipoprotein C-
II) were detected, and lipodystrophia, glycogen storage
disease, Wilson's disease, endogenous hypercorticoism,
and autoimmune disease were excluded by examination
and laboratory tests. The most probable reason for this
hypertriglyceridaemia must have been his moderate al-
cohol consumption (about 50 g/day) in combination with
other, unidentified factors. High intake of alcohol can
elevate triacylglycerol concentrations by excessive sti-
mulation of VLDL-triglyceride synthesis by the liver
(16). However, mutations in the promoter region of the
lipoprotein lipase gene (17) have not been excluded in
this patient. Since this patient repeatedly showed normal
postheparin lipolytic activity, major defects in the lipase
gene region seem to be rather unlikely. Furthermore,
mutations in the promoter region have been reported
only in patients with familial combined hyperlipidaemia
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Fig. l Time course of serum lipids and apolipoproteins during
treatment of a patient with extreme hypertriglyceridaemia.
a) Serum triacyglycerol. Dotted line indicates upper reference
value.
b) Cholesterol in VLDL (o), LDL (Δ), and HDL (D) on a semiloga-
rithmic scale. Dotted lines indicate upper reference value for
VLDL cholesterol (1) and LDL cholesterol (2).
c) Molar ratio of cholesterol to triacylglycerol in VLDL (o), LDL
(Δ), and HDL (D). Dotted lines indicate mean reference values [(1)
VLDL, (2) LDL, (3) HDL].
d) Time course of LDL cholesterol (V), apolipoprotein B (o), and
Lp(a) (o). Dotted line indicates upper reference value for LDL cho-
lesterol.
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The time course of triacylglycerol and cholesterol con-
centrations differed strikingly in this case. These data
illustrate that the half-life of lipoprotein triacylglycerol
in plasma is much shorter than the half-life of lipopro-
tein cholesterol, and thus a transient accumulation of li-
poprotein remnants in different lipoprotein densities
may occur (18, 19). In this patient, the accumulation of
cholesterol-rich remnants first mimicked type III hyper-
lipidaemia (an elevation of chylomicron remnants in ho-
mozygous carriers of apolipoprotein E2), then mimicked
familial hypercholesterolaemia (an elevation of LDL),
and finally mimicked hyperalphalipoproteinaemia. The
marked elevation of LDL cholesterol was accompanied
by an increase of Lp(a), which may be due to a competi-
tion for elimination with apolipoprotein E- and apolipo-
protein B-containing lipoproteins (chylomicron rem-
nants and VLDL remnants). The composition of all lipo-
protein species was noticeably altered during treatment,
and similar effects would be expected to appear in many
hypertriglyceridaemic patients after initiation of therapy.
Conclusion
During successful treatment of extreme hypertriglycer-
idaemia, marked changes in all lipoprotein classes were
observed. The different half-lives of cholesterol-rich and
triglyceride-rich lipoproteins can give rise to therapeutic
confusion early in the treatment of extreme hypertriglyc-
eridaemia. The accumulation of chylomicron remnants
and VLDL remnants (cholesterol-rich lipoproteins of
VLDL density) (20) can be taken for type III hyperlipid-
aemia, and a rare apolipoprotein E variant will be sus-
pected. The accumulation of LDL-like particles might
suggest a diagnosis of familial hypercholesterolaemia.
However, with the continuation of triglyceride-lowering
therapy without any other additional therapy, hyp-
ercholesterolaemia will disappear. High levels of Lp(a)
can be observed during triglyceride-lowering therapy,
and therefore Lp(a) concentration should be measured
under steady-state conditions to assess the cardiovascu-
lar risk.
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